Compare Ascendis Pharma A/S (ASND) vs iShares MSCI South Africa ETF (EZA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares MSCI South Africa ETF — how do they compare? Ascendis Pharma A/S trades at $265.33 (market cap $17.74B), while iShares MSCI South Africa ETF trades at $62.66. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| ASND | EZA | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $81.60 |
52-Week Low | $163.32 | $52.86 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EZA trades at $63.82, up 0.85% today, but technical indicators show a bearish trend with all 13 moving averages signaling sell. The stock faces resistance at $64 and support at $61. Recent news highlights South Africa's extended fuel tax cuts through June 2026, which may impact energy sector dynamics. Financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental clarity.
Outlook remains cautious due to bearish technicals and lack of current financial data. Risks include reliance on African mineral demand and geopolitical factors. Investors should await updated earnings reports for valuation insights, as the neutral sentiment from oscillators suggests limited near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →
